Live attenuated vaccine against porcine pleuropneumonia
AssigneeLaboratorios Hipra, S.A.
InventorsJaume Ribas, Sergi Bru Virgili, Enric Espuna Maso, Enrique Querol Murillo
Life of this patent
Estimating the term…
Abstract
The present invention provides a method for obtaining an immunogenic, non-haemolytic strain of Actinobacillus pleuropneumoniae which is modified, at least in a segment of the apxIA gene and optionally in a segment of the apxIIA gene that encodes a transmembrane domain of the Apx haemolytic and cytolytic exotoxins. It comprises also the strains, and the attenuated live vaccine porcine pleuorpneumonia obtained therewith.
Claims18
1-12. (canceled)
An immunogenic, non-haemolytic Actinobacillus pleoropneumoniae (App) strain comprising a mutation in at least one region of the apxIA gene, and optionally a mutation in at least one region of the apxIIA gene, wherein each region encodes a transmembrane domain of the Apx haemolytic and cytolytic exotoxins.
An immunogenic and non-haemolytic strain of Actinobacillus pleuropneumonia having the characteristics of that deposited in the Colección Española de Cultivos Tipo under registration number CECT 5985, or a mutant thereof.
An immunogenic and non-haemolytic strain of Actinobacillus pleuropneumoniae having the characteristics of that deposited in the Colección Española de Cultivos Tipo under registration number CECT 5994, or a mutant thereof.
A method for obtaining an immunogenic, non-haemolytic Actinobacillus pleuropneumoniae (App) strain comprising the steps of:
- (A) identifying transmembrane domains of Apx haemolytic and cytolytic exotoxins from a virulent App strain;
- and
- (B) introducing a mutation in at least one region of the apxIA gene of said strain, and optionally in at least one region of the apxIIA gene of said strain, wherein each region encodes a transmembrane domain of the Apx haemolytic and cytolytic exotoxins.
Dependencies are inferred from the claim text.